Erratum to “Abstract No: 305 PROMINENT: AN OPEN-LABEL, RANDOMIZED PHASE 3 TRIAL OF FELZARTAMAB IN PRIMARY MEMBRANOUS NEPHROPATHY” [Kidney International Reports Volume 11, Issue 9, Supplement, September 2026, 106950]
Erratum to “Abstract No: 305 PROMINENT: AN OPEN-LABEL, RANDOMIZED PHASE 3 TRIAL OF FELZARTAMAB IN PRIMARY MEMBRANOUS NEPHROPATHY” [Kidney International Reports Volume 11, Issue 9, Supplement, September 2026, 106950]. // Kidney International Reports. – URL: https://www.sciencedirect.com/science/article/pii/S2468024926034145?dgcid=rss_sd_all
Erratum to “Abstract No: 305 PROMINENT: AN OPEN-LABEL, RANDOMIZED PHASE 3 TRIAL OF FELZARTAMAB IN PRIMARY MEMBRANOUS NEPHROPATHY” [Kidney International Reports Volume 11, Issue 9, Supplement, September 2026, 106950]. Kidney International Reports. https://www.sciencedirect.com/science/article/pii/S2468024926034145?dgcid=rss_sd_all
“Erratum to “Abstract No: 305 PROMINENT: AN OPEN-LABEL, RANDOMIZED PHASE 3 TRIAL OF FELZARTAMAB IN PRIMARY MEMBRANOUS NEPHROPATHY” [Kidney International Reports Volume 11, Issue 9, Supplement, September 2026, 106950].” Kidney International Reports.
@article{article117324,
title = {Erratum to “Abstract No: 305 PROMINENT: AN OPEN-LABEL, RANDOMIZED PHASE 3 TRIAL OF FELZARTAMAB IN PRIMARY MEMBRANOUS NEPHROPATHY” [Kidney International Reports Volume 11, Issue 9, Supplement, September 2026, 106950]},
journal = {Kidney International Reports},
url = {https://www.sciencedirect.com/science/article/pii/S2468024926034145?dgcid=rss_sd_all}
}
ABSTRACT Approximately 5% of patients who develop renal rupture lack an identifiable underlying lesion, such as tumours, hydronephrosis, or vascular malformations. In this case report, we detail a case with a left renal rupture of a...
ABSTRACT Aim Both high and low body mass index (BMI) have been reported to be associated with a higher risk of chronic kidney disease (CKD) progression. However, whether this association varies across CKD stages remains unclear. We...
Nature Reviews Nephrology, Published online: 17 November 2026; doi:10.1038/s41581-026-01151-4 The concept of cardiovascular–kidney–metabolic (CKM) syndrome supports an integrated, multidisciplinary approach to improve patient outcomes....
ABSTRACT Introduction Patients on hemodialysis have an increased risk of sudden cardiac death and an increased cardiac arrhythmia burden due to large fluid and electrolyte shifts, especially during the long inter‐dialytic period....